Nan-Xi Li1, Yi-Ru Hu1, Wang-Ni Chen1, Bin Zhang2. 1. PsyNI Lab, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China; The Mental Health College of Guangzhou Medical University, Guangzhou, China. 2. PsyNI Lab, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China; The Mental Health College of Guangzhou Medical University, Guangzhou, China. Electronic address: zhang.bin845@foxmail.com.
Abstract
BACKGROUND: Previous studies have shown that psilocybin has antidepressant effects. In the current study, we aim to explore the dose effects of psilocybin on primary (major depression patients) and secondary depression (depressed cancer patients). METHODS: Published studies concerning psilocybin for depression were retrieved. In accordance with PRISMA guidelines, 6 databases (PubMed, Embase, Web of Science, Cochrane Library, Clinicaltrials.gov 2.3 and WanFang database) were searched for research studies published or still in progress from inception to 30 November, 2020, with language restricted to English and Chinese. Hedges' g of Beck Depression Inventory (BDI) score changes was calculated as the primary outcome. RESULTS: 7 articles were finally included, with a total of 136 participants. In terms of efficacy, Hedges' g was 1.289 (95%CI=[1.020, 1.558], heterogeneity I2=50.995%, p<0.001). As psilocybin dose increases within a certain range, the antidepressive effect declines and then increases, with 30-35 mg/70 kg achieving the optimal therapeutic effect. Subgroup analysis suggested that the antidepressive effect of psilocybin was extremely significant at a relatively high dose (30-35mg/70kg: Hedges' g=3.059, 95%CI=[2.269, 3.849], p<0.001), long-term (>1month: Hedges' g=1.123, 95%CI=[0.861, 1.385], p<0.001) and when used in primary depression patients (Hedges' g=2.190, 95%CI=[1.423, 2.957], p<0.001). LIMITATIONS: Only a small number of studies can be identified of variable quality, thus our conclusions remain preliminary. CONCLUSIONS: Our preliminary results have shown that psilocybin exerts a rapid effect in reducing depressive symptom on primary and secondary depression. The optimal dose of psilocybin may be 30-35mg/70kg or higher; future clinical trials are warranted for further evaluation on its effect.
BACKGROUND: Previous studies have shown that psilocybin has antidepressant effects. In the current study, we aim to explore the dose effects of psilocybin on primary (major depression patients) and secondary depression (depressed cancer patients). METHODS: Published studies concerning psilocybin for depression were retrieved. In accordance with PRISMA guidelines, 6 databases (PubMed, Embase, Web of Science, Cochrane Library, Clinicaltrials.gov 2.3 and WanFang database) were searched for research studies published or still in progress from inception to 30 November, 2020, with language restricted to English and Chinese. Hedges' g of Beck Depression Inventory (BDI) score changes was calculated as the primary outcome. RESULTS: 7 articles were finally included, with a total of 136 participants. In terms of efficacy, Hedges' g was 1.289 (95%CI=[1.020, 1.558], heterogeneity I2=50.995%, p<0.001). As psilocybin dose increases within a certain range, the antidepressive effect declines and then increases, with 30-35 mg/70 kg achieving the optimal therapeutic effect. Subgroup analysis suggested that the antidepressive effect of psilocybin was extremely significant at a relatively high dose (30-35mg/70kg: Hedges' g=3.059, 95%CI=[2.269, 3.849], p<0.001), long-term (>1month: Hedges' g=1.123, 95%CI=[0.861, 1.385], p<0.001) and when used in primary depression patients (Hedges' g=2.190, 95%CI=[1.423, 2.957], p<0.001). LIMITATIONS: Only a small number of studies can be identified of variable quality, thus our conclusions remain preliminary. CONCLUSIONS: Our preliminary results have shown that psilocybin exerts a rapid effect in reducing depressive symptom on primary and secondary depression. The optimal dose of psilocybin may be 30-35mg/70kg or higher; future clinical trials are warranted for further evaluation on its effect.
Authors: Vojtěch Viktorin; Inga Griškova-Bulanova; Aleksandras Voicikas; Dominika Dojčánová; Peter Zach; Anna Bravermanová; Veronika Andrashko; Filip Tylš; Jakub Korčák; Michaela Viktorinová; Vlastimil Koudelka; Kateřina Hájková; Martin Kuchař; Jiří Horáček; Martin Brunovský; Tomáš Páleníček Journal: J Pers Med Date: 2022-06-19
Authors: Manon van den Berg; Igor Magaraggia; Rudy Schreiber; Todd M Hillhouse; Joseph H Porter Journal: Psychopharmacology (Berl) Date: 2022-03-29 Impact factor: 4.415